BioNTech wants authorization to vaccinate minors from 2 years of age
The BioNTech / Pfizer vaccine was the first to be licensed for ages 16 and over worldwide.
German pharmaceutical company BioNTech plans to apply this fall to authorize its coronavirus vaccine for children from the age of two, German public television "ZDF" reported.
The company, which produces and distributes its covid vaccine around the world together with the American pharmaceutical company Pfizer, explained that the results of the tests they are carrying out with minors could be in September.
The BioNTech / Pfizer vaccine was the first to be licensed for ages 16 and older globally at the end of last year and the first to receive the green light this May for children ages 12 to 16 (first in the US and then in the EU).
In Germany, however, this formula is not recommended by the Permanent Commission for Vaccination (Stiko) for all minors between 12 and 16 years of age, but only for those with previous illnesses for whom an infection with Sars-CoV2 may be a special risk.
BioNTech and Pfizer began this year the tests in children under 12 years of age, in a staggered manner, by age groups, and in descending order, to verify the effectiveness of their vaccine in different groups and the necessary doses, explained the German company.
The pharmaceutical companies also plan to study throughout this year the results of their formula against the coronavirus in minors between six months and two years.
The company, which produces and distributes its covid vaccine around the world together with the American pharmaceutical company Pfizer, explained that the results of the tests they are carrying out with minors could be in September.
The BioNTech / Pfizer vaccine was the first to be licensed for ages 16 and older globally at the end of last year and the first to receive the green light this May for children ages 12 to 16 (first in the US and then in the EU).
In Germany, however, this formula is not recommended by the Permanent Commission for Vaccination (Stiko) for all minors between 12 and 16 years of age, but only for those with previous illnesses for whom an infection with Sars-CoV2 may be a special risk.
BioNTech and Pfizer began this year the tests in children under 12 years of age, in a staggered manner, by age groups, and in descending order, to verify the effectiveness of their vaccine in different groups and the necessary doses, explained the German company.
The pharmaceutical companies also plan to study throughout this year the results of their formula against the coronavirus in minors between six months and two years.
